Aesica Joins Forces with Britest
News Feb 15, 2013
Aesica has announced that it will be joining Britest in a collaboration where members share knowledge and risk in defining innovative solutions to key manufacturing challenges.
Britest has already engaged with 22 leading global chemical and pharmaceutical organizations together with a number of academic organizations.
The partnerships are designed to utilize and further develop Britest’s innovative tools and methodologies to support whole process understanding.
In particular, Aesica will be utilizing Britest’s expertise to identify new approaches and technologies that drive major improvements in API manufacturing processes.
The Aesica Innovation Board (AIB) aims to identify and commercialize new innovative technologies that help to bridge the growing R&D gap though industry and academic collaborations.
Joining Britest will increase the AIB’s access to applicable, relevant technologies and strengthen the organizations relationships throughout the industry.
Dr Barrie Rhodes, Aesica Director of Technology Development said: “At Aesica we aspire to develop and implement new technologies and improve processes to support business growth. Following the successful demonstration of the Britest approach on a key Active Pharmaceutical Ingredient process at our Cramlington site, we are now looking forward to engaging fully in the Britest collaboration and implementing the Britest approach across a range of processes.”
Sue Fleet, Britest CEO said: “I am delighted to welcome Aesica Pharmaceuticals as our latest company member. With a clear focus on innovation and collaboration, we look forward to supporting Barrie and his colleagues at Aesica in driving innovative thinking and deriving full value from their membership of Britest.”
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE